Scarabin, P.Y., Oger, E., Plu-Bureau, G. and ESTHER Study Group (2003) Differential Associations of Oral Andtransdermal Oestrogen Replacement Therapy with Venous Thromboembolism Risk. The Lancet, 362, 428-432.
https://doi.org/10.1016/S0140-6736(03)14066-4

has been cited by the following article:

• TITLE: Review Venous Thromboembolism Risk with Anti-Osteoporosis Drugs

  AUTHORS: Kawtar Nassar, Wafae Rachidi, Saadia Janani, Ouafa Mkinsi

  KEYWORDS: Osteoporosis, Venous Thrombosis, Drugs, Estrogens, Progestins

  JOURNAL NAME: Open Journal of Rheumatology and Autoimmune Diseases, Vol.8 No.4, October 30, 2018

  ABSTRACT: Osteoporosis is the most common skeletal diseases, predisposing the patient to an increased risk of fractures. It is an important health issue linked to increased morbidity and mortality. Prevention and treatment strategies are now well defined and are always updating. Indeed, the therapeutic decision is based on the individual risk of fracture, efficiency and degree of therapeutic tolerance. However, some side effects, although rare can be attributed to drugs used. The benefit and risks of prescription drugs can be optimized by choosing the right time and the right treatment. The purpose of this article is the study of thromboembolic risk of various drugs recommended in osteoporosis. Furthermore we discuss preventive measures, and the different approaches after the first event.